ArticleJAMIA open2025
Analyzing the impact of pharmacogenomics-guided nonsteroidal anti-inflammatory drug alerts in clinical practice.
Article in JAMIA open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study evaluates response rates of pharmacogenomics (PGx) nonsteroidal anti-inflammatory drugs (NSAIDs) clinical decision support (CDS) alerts at Sanford Health from May 2020 to December 2024. Materials and Methods: A retrospective analysis was conducted on PGx NSAIDs interruptive alerts. Response options were classified into five categories (1) continuation of triggering NSAID order, (2) dose modification, (3) alternative NSAID ordered without PGx implications, (4) alternative analgesic (ie, opioid) ordered, and (5) discontinuation of NSAID without alternative therapy. Results: The study analyzed 2361 alert instances from 978 patients. The most common response was discontinuing NSAID without alternative therapy (43%). Dose modifications and orders for alternative analgesics comprised 2.57% and 14.67% of responses, respectively. The initial acceptance rate was 62.6%. Prior NSAID use significantly impacted override rates (60% vs 40%, Discussion: PGx NSAIDs CDS alert acceptance rates were higher compared to general CDS acceptance rates. This study highlights opportunities for continuous improvement including optimizing alert modality, modifying alert criteria to include look-back periods, and implementing genetically adapted ordersets. Conclusion: The initial acceptance rate of PGx NSAIDs CDS alerts was 62.6%, however, with significantly higher acceptance rates in NSAID naïve patients (62.6% vs 96.1%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.